Analyst Price Targets — ASTH
Latest News for ASTH
Astrana Health is rated a buy, trading at a 46% discount to peers despite sector-wide reserve releases clarifying earnings quality concerns. ASTH's Care Enablement platform drove G&A costs from 7.75% to 5.57% of revenue, quadrupling third-party revenue year-over-year and supporting durable profit at scale. Organic growth is driven by a mix-shift into full-risk capitation, with management projecting ongoing…
Astrana Health, Inc. (ASTH) Q2 2026 Earnings Call Transcript
Astrana Health, Inc. (ASTH) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.19 per share a year ago.
Astrana Health NASDAQ: ASTH reported second-quarter 2026 revenue of $973 million, up 49% from a year earlier, while adjusted EBITDA increased 43% to $69 million. Adjusted diluted earnings per share reached a record $0.80, up 45% year over year, as the company cited growth in value-based care arrangements, medical-cost management, Prospect Health acquisition synergies and operating leverage.
Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ASTH.
U.S. House Trading
No House trades found for ASTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.